Scarica l'app Stockscreener
7.12
6.91%
0.46
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ADIL Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$6.66
Aprire:
$6.61
Volume 24 ore:
48,386
Relative Volume:
0.11
Capitalizzazione di mercato:
$18.70M
Reddito:
-
Utile/perdita netta:
$-7.77M
Rapporto P/E:
-0.7189
EPS:
-9.9046
Flusso di cassa netto:
$-6.52M
1 W Prestazione:
+27.14%
1M Prestazione:
+87.37%
6M Prestazione:
+257.79%
1 anno Prestazione:
-17.78%
Intervallo 1D:
$6.27
$7.20
Intervallo di 1 settimana:
$5.30
$7.20
Portata 52W:
$1.31
$10.75
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
Nome
Adial Pharmaceuticals Inc
Settore
Industria
Telefono
434-422-9800
Indirizzo
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Compare ADIL vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADIL
Adial Pharmaceuticals Inc
|
7.12 | 15.49M | 0 | -7.77M | -6.52M | -9.9046 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-14 | Iniziato | Rodman & Renshaw | Buy |
| 2018-10-30 | Iniziato | Maxim Group | Buy |
| 2018-10-11 | Iniziato | Dawson James | Buy |
Adial Pharmaceuticals Inc Borsa (ADIL) Ultime notizie
Adial Pharmaceuticals Faces Nasdaq Listing Compliance Challenge - TipRanks
Adial Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Adial Pharmaceuticals (ADIL) Jumps 15% as Trading Volume AcceleratesFade Trade - vinanet.vn
Adial Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Adial Closes $32M Tranche of $64M Financing for Ulcerative Colitis Drug Development - Minichart
Form 8K Adial Pharmaceuticals Inc For: 17 August By Investing.com - Investing.com Nigeria
Weekly Recap: Cash shortfall, warrant reliance and CEO succession, CFO exit - TradingView
Adial Reports $52 Million Second-Quarter Net Loss After Azora Acquisition - Quiver Quantitative
Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update - The Manila Times
ADIL Q1 2026 Earnings: EPS Surprise Amid Revenue AbsenceDividend Growth Analysis - vinanet.vn
Adial Pharmaceuticals (ADIL) Slides 9.3% as Biotech Volatility ReturnsSector Leader Stocks - dars.gov.et
Adial Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Adial Pharmaceuticals (NASDAQ: ADIL) lifts cash to $28.7M but flags going‑concern risk - Stock Titan
Form 8K Adial Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Nigeria
Adial Pharmaceuticals plans leadership changes tied to annual meeting vote - Investing.com
Adial Pharmaceuticals Plans Major Leadership and Board Transition - TipRanks
Adial PharmaceuticalsAs Of Aug 10, Anticipates Termination Of CEO Cary Claiborne After 2026 Annual Meeting - TradingView
ADIL Q1 2026 Earnings: Narrower-than-Expected Loss Delivers 46.85% Positive SurpriseCash Flow Report - Vinanet
Adial Pharmaceuticals Acquires Azora Therapeutics in Stock-and-Preferred Deal - Minichart
Adial Pharmaceuticals announces annual shareholder meeting - Bitget
Form 8K Adial Pharmaceuticals Inc For: 11 August By Investing.com - Investing.com Canada
Adial Pharmaceuticals (NASDAQ: ADIL) outlines Azora merger, heavy dilution and $53M share overhang - Stock Titan
Adial Pharmaceuticals Inc expected to post a loss of $1.03 a shareEarnings Preview - TradingView
Adial Pharmaceuticals (ADIL) Plunges 17% as Shares Test Key $3.78 Support LevelVolatility Breakout Picks - dars.gov.et
Adial Pharmaceuticals Price Target Announced at $11.00/Share by Alliance Global Partners - Moomoo
Adial Pharmaceuticals Initiated at Buy by Alliance Global Partners - Moomoo
A. G. P. Initiates Adial Pharmaceuticals(ADIL.US) With Buy Rating, Announces Target Price $11 - moomoo.com
ADIL Q1 2026 Earnings: EPS Beats Estimates Sharply, But Revenue Remains AbsentRevenue Growth Outlook - vinanet.vn
ADIL Q1 2026 Earnings: Narrower-than-Expected Loss Fuels 4.44% Share UptickFinancial Data - Vinanet
Adial Pharmaceuticals Inc (ADIL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Adial Pharmaceuticals Inc (ADIL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Adial Pharmaceuticals Inc (ADIL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Adial Pharmaceuticals Inc (ADIL) Institutional Confidence - TradingKey
Adial Pharmaceuticals Inc (ADIL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ADIL|Adial Pharmaceuticals Inc|Price:2.860|Chg%:+0.080 - TradingKey
Adial Pharmaceuticals Inc (ADIL) Cash Flow - tradingkey.com
ADIL|Adial Pharmaceuticals Inc|Price:4.400|Chg%:+0.090 - TradingKey
Adial Pharmaceuticals, Inc Revenue Breakdown – NASDAQ:ADIL - TradingView
ADIL Q1 2026 Earnings: EPS Surprise Beat Amid Ongoing Clinical DevelopmentRevenue Guidance Update - vinanet.vn
Adial Pharmaceuticals (ADIL) Slides 1.09% as Stock Tests Key Support ZoneExhaustion Gap - dars.gov.et
Adial Pharmaceuticals (ADIL) Edges Higher as Shares Test Key Resistance ZoneVolume Profile - dars.gov.et
Adial Pharmaceuticals (ADIL) Slides 3.57%: Testing Key Support Near $2.56Accumulation Line - dars.gov.et
ADIL Q1 2026 Earnings: Better-Than-Expected Loss Highlights Cost Discipline Amid Pre-Revenue StageTangible Book Value - vinanet.vn
Form 4 Adial Pharmaceuticals Inc For: 16 July By Investing.com - Investing.com South Africa
Coastlands Capital buys $8,690 of Adial Pharmaceuticals stock By Investing.com - Investing.com Nigeria
Coastlands Capital buys $8,690 of Adial Pharmaceuticals stock - Investing.com
Coastlands Capital (NASDAQ: ADIL) buys 3,233 ADIAL shares in open market - Stock Titan
Adial Pharmaceuticals (ADIL) Edges Higher on Potential Breakout Above Key ResistanceInside Day Breakout - dars.gov.et
Adial Pharmaceuticals Inc (ADIL) Q1 2026 Earnings: Narrower Loss Than Expected Boosts SharesSaaS Earnings Trends - dars.gov.et
Form 4 Adial Pharmaceuticals Inc For: 13 July By Investing.com - Investing.com Nigeria
10% owner Coastlands Capital buys $32,637 in Adial Pharmaceuticals By Investing.com - Investing.com Nigeria
Adial Pharmaceuticals Inc Azioni (ADIL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Adial Pharmaceuticals Inc Azioni (ADIL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Coastlands Capital LP | 10% Owner |
Jul 16 '26 |
Buy |
2.75 |
1,233 |
3,391 |
388,308 |
| Coastlands Capital LP | 10% Owner |
Jul 09 '26 |
Buy |
2.79 |
10,053 |
28,048 |
383,375 |
| Coastlands Capital LP | 10% Owner |
Jul 10 '26 |
Buy |
2.70 |
1,700 |
4,590 |
385,075 |
| Coastlands Capital LP | 10% Owner |
Jun 29 '26 |
Buy |
2.60 |
25,000 |
65,000 |
373,322 |
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):